Precision CRISPR: Drug Development & Gene Therapy Congress returned for the 3rd time in October, just in time to face the building excitement in getting CRISPR gene therapy into the clinic. Attendees took part in the conversations around the future of CRISPR gene editing in Europe and the rest of the world.
Through a dynamic program of focused sessions, interactive discussions and networking opportunities, attendees left this meeting with a deep understanding of:
VP & & Senior Principal
Eric Paul Bennet
"Gene Repair in Human Hematopoietic Stem Cells"
An exciting session from Jacob Corn, where he will share his findings on systematic approach for generating knock-ins in stem cells; Identifying and improving precision of HDR events; And the Use of live imaging and gene editing to explore cell states.
"Detection of in vitro and ex vivo Cellular indel Profiles and Dynamics Induced By Different CRISPR/Cas9 Delivery Formats"
Learn from Eric Paul Bennet, about methodologies for absolute identification of cellular Cas9 induced indel events and ask about the In Vitro and Ex Vivo Indel formation, dynamics and profiles induced by various CRISPR/
Cas9 delivery formats
"Single-Cell CRISPR Sequencing in Drug Discovery"
Talk with Quin Wills, about how Genetic epidemiology and CRISPR screens still struggle to comment about drug target modifiers. Find out how he is dissecting out the cross-talk between metabolic pathways to understand target
interactions, with liver organoid models.
T: +44 (0)20 3141 8700
© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.